よむ、つかう、まなぶ。
資料4-1 オキサリプラチン (22 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00024.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第52回 8／31）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
taxanes, and irinotecan. Gastric Cancer 2018; 21: 1050-7.
21) Tsuji K, et al. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer
refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. Jpn J Clin
Oncol 2012; 42: 686-90.
22) Osumi H, et al. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric
cancer with massive ascites or inadequate oral intake. Onco Targets Ther 2018; 11: 8301-7.
23) Masuishi T, et al. FOLFOX as first-line therapy for gastric cancer with severe
peritoneal metastasis. Anticancer Res 2017; 37: 7037-42.
24) Xu HB, et al. Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin
plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled
trials. Eur J Clin Pharmacol 2015; 71: 589-601.
25) Caponigro F, et al. Gastric cancer. Treatment of advanced disease and new drugs. Front
Biosci. 2005; 10: 3122-6.
26) Louvet C, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced
or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-8.
27) Al-Batran S-E, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin
in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658-63.
28) Scheithauer W, et al. The role of oxaliplatin in the management of upper gastrointestinal
tract malignancies. Colorectal Dis 2003; 5: 36-44.
29) Artru P, et al. Oxaliplatin (OXA), 5-fluoro-uracil (FU) and folinic acid (FA) (FOLFOX 6) in
advanced/metastatic gastric carcinoma (A/MGC) patients (Pts): final results of a multicenter
phase II study. Proc Am Soc Clin Oncol 2001; 20: 164a.
30) Bécouarn Y, et al. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit
Rev Oncol Hematol 2001; 40: 265-72.
31) Shah MA. Update on Metastatic Gastric and Esophageal Cancers. J Clin Oncol 2015; 33: 17609.
32) Van Cutsem E, et al. Gastric cancer. Lancet 2016; 388: 2654-64.
33) De Vita, Hellman and Rosenberg’s Cancer: Principles & Practice of Oncology 11th edition. 2019
34) 新臨床腫瘍学―がん薬物療法専門医のために. 改訂 6 版. 日本腫瘍学会編 2021
35) 胃癌治療ガイドライン 改訂第 6 版. 日本胃癌学会編 2021
22
21) Tsuji K, et al. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer
refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study. Jpn J Clin
Oncol 2012; 42: 686-90.
22) Osumi H, et al. Modified FOLFOX6 as a first-line treatment for patients with advanced gastric
cancer with massive ascites or inadequate oral intake. Onco Targets Ther 2018; 11: 8301-7.
23) Masuishi T, et al. FOLFOX as first-line therapy for gastric cancer with severe
peritoneal metastasis. Anticancer Res 2017; 37: 7037-42.
24) Xu HB, et al. Capecitabine plus oxaliplatin (XELOX) compared with 5-fluorouracil/leucovorin
plus oxaliplatin (FOLFOXs) in advanced gastric cancer: meta-analysis of randomized controlled
trials. Eur J Clin Pharmacol 2015; 71: 589-601.
25) Caponigro F, et al. Gastric cancer. Treatment of advanced disease and new drugs. Front
Biosci. 2005; 10: 3122-6.
26) Louvet C, et al. Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced
or metastatic gastric cancer patients. J Clin Oncol 2002; 20: 4543-8.
27) Al-Batran S-E, et al. Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin
in patients with advanced gastric cancer. J Clin Oncol 2004; 22: 658-63.
28) Scheithauer W, et al. The role of oxaliplatin in the management of upper gastrointestinal
tract malignancies. Colorectal Dis 2003; 5: 36-44.
29) Artru P, et al. Oxaliplatin (OXA), 5-fluoro-uracil (FU) and folinic acid (FA) (FOLFOX 6) in
advanced/metastatic gastric carcinoma (A/MGC) patients (Pts): final results of a multicenter
phase II study. Proc Am Soc Clin Oncol 2001; 20: 164a.
30) Bécouarn Y, et al. Oxaliplatin: available data in non-colorectal gastrointestinal malignancies. Crit
Rev Oncol Hematol 2001; 40: 265-72.
31) Shah MA. Update on Metastatic Gastric and Esophageal Cancers. J Clin Oncol 2015; 33: 17609.
32) Van Cutsem E, et al. Gastric cancer. Lancet 2016; 388: 2654-64.
33) De Vita, Hellman and Rosenberg’s Cancer: Principles & Practice of Oncology 11th edition. 2019
34) 新臨床腫瘍学―がん薬物療法専門医のために. 改訂 6 版. 日本腫瘍学会編 2021
35) 胃癌治療ガイドライン 改訂第 6 版. 日本胃癌学会編 2021
22